Study Details
Study of Ipragliflozin in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
Clinicaltrials.gov ID
Astellas Study ID
1941-MA-3054
EudraCT ID
N/A
Condition
Adult Onset Diabetes
Phase
Phase 4
Age
20 years - 74 years
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Jul 2016 - Nov 2017
Masking
None (Open Label)
Enrollment number
103
Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Study of Ipragliflozin in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site JP00010
Kanagawa, Japan
Site JP00007
Gunma, Japan
Site JP00011
Tokyo, Japan
Site JP00013
Tochigi, Japan
Site JP00005
Tochigi, Japan
Site JP00015
Shiga, Japan
Site JP00012
Tokyo, Japan
Site JP00008
Hiroshima, Japan
Site JP00001
Tokyo, Japan
Site JP00004
Osaka, Japan
Site JP00006
Tokyo, Japan
Site JP00003
Mie, Japan
Site JP00014
Tokyo, Japan
Site JP00002
Tochigi, Japan
Site JP00009
Hyogo, Japan